Houston researchers report promising first in-human trial for implantable cancer therapy (opens original article in a new tab)

Houston researchers conducted the first in-human trial of an implantable cancer therapy called AVB-001, which uses encapsulated cells to release IL-2 in the peritoneal cavity, showing safety and some clinical benefit in patients with serous ovarian carcinoma.

• AVB-001 uses encapsulated cells to release IL-2 in the peritoneal cavity for localized cancer treatment.
• The trial involved 14 patients with serous ovarian carcinoma, half of whom had stabilized cancer, with no life-threatening events.
• Researchers plan further testing with higher doses or combinations to optimize the therapy's effectiveness.